PressRelease
Cleanascite™Use Helps Identity a Distinct Cancer-cell Lipid Metabolism Archetype
MONMOUTHJUNCTION, NJ, July 25, 2025 — In this study, researchers haveuncovered critical mechanisms driving immune suppression inhepatocellular carcinoma (HCC), highlighting the role of oxidized LDL(oxLDL) in promoting protumor macrophage polarization. Central to the
study's methodology was the use of Cleanascite™, alipid-binding reagent from Biotech Support Group, which enabled theresearchers to efficiently isolate and study lipid-influences fromtumor interstitial fluid (TIF).
Thestudy, entitled “Metabolismarchetype cancer cells induce protumor TREM2+ macrophages via oxLDLmediated metabolic interplay in hepatocellular carcinoma”and conducted by an international team led by Fudan University,identified a distinct "metabolism archetype" of cancercells characterized by high lipid metabolism and cholesterolbiosynthesis. These cancer cells generate oxLDL, which in turnpolarizes TREM2+ tumor-associated macrophages (TAMs) via theTREM2–SYK–CEBPα signaling axis. This interplay results in immunesuppression and resistance to immunotherapy in both human and mousemodels of HCC.
Cancercells often display a
marked upregulation in lipid metabolism, amechanism that not only promotes their proliferation but also manipulates stromal cells, like tumor-associated macrophages (TAMs),contributing to an immuno suppressive tumor microenvironment (TME).To interrogate the lipidomic environment of the TME, the researchersutilized Cleanascite™ to selectively remove lipids and confirm thelipid-dependence of TREM2+ TAM polarization. HCC-derived TIF potentlyinduced the expression of TREM2 and SPP1 in macrophages, which wasattributed to lipids…(Fig.). Consequently, Cleanascite™ enabled amore precise functional dependency measurement, strengthening thestudy’s mechanistic insights.
“Itis very rewarding to see how this study not only sheds light on theimmunometabolic dynamics of hepatocellular carcinoma, but potentiallytowards novel therapeutic approaches that target metabolic crosstalkbetween cancer cells and immune cells. Importantly, the studyunderscores the growing importance of Cleanascite™ in advancingcancer metabolism and tumor microenvironment research.,” stated Dr.Swapan Roy, President and Founder of Biotech Support Group. “Unliketraditional solvent-based methods, Cleanascite™ provides anaqueous, cell-compatible reagent, preserving cellular function andphenotypic integrity after removal of lipids. With suchcompatibility in live cell models, Cleanascite™ enables researchersto confidently dissect the complex roles of lipid metabolism indisease mechanisms.”
Foradditional product details, visit:
Cleanascite™Lipid Removal Reagent
AboutBiotech Support Group LLC
BiotechSupport Group develops innovative sample preparation technologiesthat address the emerging needs of proteomics, biomarker discovery,and personalized medicine. Flagship products include Cleanascite™for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum proteindepletion, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NRicher™ for low abundance, family specific, and targetedproteome enrichment.These products support translational research by simplifyingworkflows and improving sample quality for downstream analysis.
ForBusiness Development Inquiries:
Matthew Kuruc
Phone:732-274-2866
Email: [email protected]
Keywords: Cleanascite™, lipid depletion, tumor microenvironment, tumor-associated macrophages, TREM2+TAM polarization, tumor interstitial fluid, hepatocellular carcinoma, Biotech Support Group